Literature DB >> 26247456

Comorbidity and Health Care Resource Use Among Commercially Insured Non-Elderly Patients With Diabetic Macular Edema.

Christopher J Wallick, Ryan N Hansen, Joanna Campbell, Szilárd Kiss, Jonathan W Kowalski, Sean D Sullivan.   

Abstract

BACKGROUND AND
OBJECTIVE: Diabetic macular edema (DME) is a leading cause of blindness for non-elderly adults; however, health care-associated burden data from this population is lacking. The authors describe health care-associated burden in non-elderly patients with DME compared to those with diabetes and no DME. PATIENTS AND METHODS: In this retrospective, large-cohort study examines enrollment and health care claims (2007 to 2011) from a national database of insured patients aged 18 to 63 years (mean: 51). Comorbidity and health care utilization differences between patients with DME (n = 24,326) and matched controls with diabetes but no DME (n = 122,710) were analyzed over 1 and 3 years.
RESULTS: DME patients had significantly more baseline comorbidities, and generally developed them at a higher rate over the study. Health care resource utilization rates were significantly higher in DME patients for every category analyzed. Patients with DME averaged more than 10 health care visits more than those with diabetes but no DME (25.5 vs 14.9; P < .001).
CONCLUSION: Working-age patients with DME exhibit a complicated comorbidity profile and high associated burden of health care consumption. Considering this burden is critical for managing this complex population. Copyright 2015, SLACK Incorporated.

Entities:  

Mesh:

Year:  2015        PMID: 26247456     DOI: 10.3928/23258160-20150730-09

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  15 in total

1.  A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.

Authors:  David G Callanan; Anat Loewenstein; Sunil S Patel; Pascale Massin; Borja Corcóstegui; Xiao-Yan Li; Jenny Jiao; Yehia Hashad; Scott M Whitcup
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-08       Impact factor: 3.117

2.  Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review.

Authors:  Nikolaos Maniadakis; Evgenia Konstantakopoulou
Journal:  Pharmacoeconomics       Date:  2019-08       Impact factor: 4.981

Review 3.  Molecular Mechanisms Mediating Diabetic Retinal Neurodegeneration: Potential Research Avenues and Therapeutic Targets.

Authors:  Harshini Chakravarthy; Vasudharani Devanathan
Journal:  J Mol Neurosci       Date:  2018-10-06       Impact factor: 3.444

4.  Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world study.

Authors:  Tunde Peto; Toks Akerele; Alexandros Sagkriotis; Sofia Zappacosta; Andreas Clemens; Usha Chakravarthy
Journal:  Diabet Med       Date:  2021-12-15       Impact factor: 4.213

5.  Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema.

Authors:  Szilárd Kiss; Hitesh S Chandwani; Ashley L Cole; Vaishali D Patel; Orsolya E Lunacsek; Pravin U Dugel
Journal:  Clin Ophthalmol       Date:  2016-12-07

6.  Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1).

Authors:  Kevin J Blinder; Pravin U Dugel; Sanford Chen; J Michael Jumper; John G Walt; David A Hollander; Lanita C Scott
Journal:  Clin Ophthalmol       Date:  2017-02-21

7.  Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review.

Authors:  Shwu-Jiuan Sheu; Cheng-Kuo Cheng; Hsi-Kung Kuo; Ching-Yao Tsai; Tai-Chi Lin; Jonathan Tan; Hitesh Chandwani; Michael Adena; Shih-Jen Chen
Journal:  Clin Ophthalmol       Date:  2018-10-29

8.  TREATMENT PATTERNS AND 2-YEAR VISION OUTCOMES WITH BEVACIZUMAB IN DIABETIC MACULAR EDEMA: An Analysis From a Large U.S. Integrated Health Care System.

Authors:  Donald S Fong; Tiffany Q Luong; Richard Contreras; Jennifer J Jimenez; Peter H Custis; Vaishali Patel; Joanna H Campbell
Journal:  Retina       Date:  2018-09       Impact factor: 4.256

9.  A Multicenter, Cross-Sectional Study of the Incidence of Major Macular Diseases That Cause Visual Impairment and Require Therapeutic Intervention in Greece: The ADVICE Study.

Authors:  Dimitrios A Karagiannis; Meropi Lygerou; Georgios Papadopoulos; Stamatina A Kabanarou; Miltiadis Aspiotis; Doukas C Dardabounis; Panagiotis G Minakakis; Sofia I Spai; Chrysanthi Koutsandrea; Panagiotis Oikonomidis; Georgia N Pantelopoulou; Olga C Kousidou; Miltiadis Tsilimbaris
Journal:  Clin Ophthalmol       Date:  2020-05-25

Review 10.  Diabetic macular edema: Evidence-based management.

Authors:  David J Browning; Michael W Stewart; Chong Lee
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.